



February 22, 2013

Acura Pharmaceuticals to Present at the Cowen Health Care Conference on March 5, 2013

PALATINE, IL -- (Marketwire) -- 02/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address [medication abuse and misuse](#), announced today that the Company will present at the Cowen and Company Health Care Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013. Bob Jones, Acura Pharmaceutical's Chief Executive Officer, will provide a company update at 8:40AM Eastern Time. In advance of this presentation the Company plans to report financial results for the fourth quarter and fiscal year ended December 2012 following the close of markets on Monday, March 4, 2013.

A live webcast of the presentation will be available through the "[Investors](#)" page of Acura's website: www.acurapharm.com. An archived version of the presentation will be available for 30 days after the event.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE™ technologies. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXECTA® (oxycodone HCl tablets) which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products containing other opioids.

In December 2012, the Company commenced commercialization of Nexafed® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE™ technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine.

The trademark OXECTA® is owned by Pfizer Inc.

Contact:

for Acura Investor Relations

Email Contact

847-705-7709

for Acura Media Relations

Email Contact

847-705-7709

Source: Acura Pharmaceuticals, Inc.

News Provided by Acquire Media